Preparation of Graded Zirconia—Hydroxyapatite Composite Bioceramic and Its Immunocompatibility in vitro
Source abstract
Abstract
To obtain immunocompatibility, graded zirconia—hydroxyapatite (ZrO 2 -HA) composite bioceramic and simplex ZrO 2 -HA composite bioceramic are prepared. Peripheral blood mononuclear cells (PBMCs) harvested from healthy individuals are cultured with the two ceramic extracts to assess their effect on the transformation of lymphocytes, apoptotic ratio, CD69 expression, and expression of cytokine of TNFα and IL-6, with or without phytohemoagglutinin (PHA)-stimulated cells. Ceramic extracts did not activate the resting lymphocytes, whereas the response of the PHA-stimulated cells was significantly modified. The PBMCs activated by graded ZrO2-HA composite bioceramic is noticeably smaller than that by simplex ZrO2-HA composite bioceramic; these results, however can only be seen under the amplified effect of PHA-stimulation.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · biodegradable polymer synthesis and properties · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Orthopaedics, Second Affiliated Hospital Zhejiang University, 310009 Hangzhou, China
Department of Orthopaedics, Second Affiliated Hospital Zhejiang University, 310009 Hangzhou, China,
School of Materials Science and Engineering Shanghai University, 200072 Shanghai, China
Department of Orthopaedics, Xiaoshan Traditional Chinese Medical Hospital, 311201 Hangzhou, China
References (30)
Show source-provided references
1. 10.1002/jbm.82025070310.1002/jbm.820250703 ↗
2. 10.1016/0142-9612(96)00042-710.1016/0142-9612(96)00042-7 ↗
3. 10.1016/0043-1648(91)90151-J10.1016/0043-1648(91)90151-J ↗
4. 10.1016/S0142-9612(98)00182-310.1016/S0142-9612(98)00182-3 ↗
5. Richter, H.G. · Ceram. Trans · 1995 · 48 · 73
6. 10.1002/jbm.82023010510.1002/jbm.820230105 ↗
7. 10.1016/0267-6605(93)90073-G10.1016/0267-6605(93)90073-G ↗
8. 10.1016/0267-6605(93)90074-H10.1016/0267-6605(93)90074-H ↗
9. 10.1016/S0928-4931(02)00031-010.1016/S0928-4931(02)00031-0 ↗
10. 10.1016/S0142-9612(02)00381-210.1016/S0142-9612(02)00381-2 ↗
11. 10.1016/S0142-9612(02)00428-310.1016/S0142-9612(02)00428-3 ↗
12. 10.1016/S0167-577X(99)00197-410.1016/S0167-577X(99)00197-4 ↗
13. 10.1016/S0142-9612(98)00166-510.1016/S0142-9612(98)00166-5 ↗
14. 10.1016/0142-9612(96)82729-310.1016/0142-9612(96)82729-3 ↗
15. Kumar, R.R.
16. 10.1002/jor.110015061310.1002/jor.1100150613 ↗
17. 10.1097/00003086-199704000-0001710.1097/00003086-199704000-00017 ↗
18. 10.1039/jm993030004310.1039/jm9930300043 ↗
19. Wu, J.-M. · Science · 1998 · 23 · 3771
20. 10.1016/S0142-9612(01)00215-010.1016/S0142-9612(01)00215-0 ↗
21. FDAF-Center for Devices and Radiological Health : Guidance for Industry and FDA Reviewers. Immunotoxicity Testing Guidance. May 6, 1999. pp. 1—16.
22. 10.1163/15685620074382310.1163/156856200743823 ↗
23. 10.1016/S0736-0266(02)00241-310.1016/S0736-0266(02)00241-3 ↗
24. 10.1084/jem.167.5.157210.1084/jem.167.5.1572 ↗
25. 10.1002/(SICI)1097-0320(19961215)26:4<305::AID-CYTO11>3.0.CO;2-V10.1002/(SICI)1097-0320(19961215)26:4<305::AID-CYTO11>3.0.CO;2-V ↗
26. Blanka, R. · Advanced Drug Delivery Reviews · 2000 · 42 · 65
27. 10.1016/0167-5699(90)90173-710.1016/0167-5699(90)90173-7 ↗
28. Abbas, A.K. · 1997
29. 10.1016/S0169-409X(96)00404-810.1016/S0169-409X(96)00404-8 ↗
30. 10.1038/ki.1990.1210.1038/ki.1990.12 ↗